Aakash Desai, MD, MPH
@ADesaiMD
Followers
4,911
Following
1,259
Media
1,287
Statuses
8,641
Thoracic/Phase 1 Oncologist @ONealCancerUAB , Asst Prof @UABMedicine | Alum @MayoHemeOnc @UConnIM @MDAndersonNews | Co-Host @HemOncFellows @LungCancerRX
Rochester, MN
Joined June 2019
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
#Mülakatsız68BinÖğretmenUlusta
• 675139 Tweets
東京15区
• 122804 Tweets
#光る君へ
• 73941 Tweets
FINALLY FIND BIU
• 58694 Tweets
立憲民主党
• 56020 Tweets
島根1区
• 53464 Tweets
衆議院補欠選挙
• 53033 Tweets
衆院3補選
• 49314 Tweets
Tottenham
• 45894 Tweets
Marc
• 42470 Tweets
当選確実
• 39451 Tweets
Spurs
• 39114 Tweets
Marquez
• 25650 Tweets
自民全敗
• 24037 Tweets
江東区民
• 22281 Tweets
須藤元気
• 21509 Tweets
政権交代
• 18096 Tweets
ZETA
• 17901 Tweets
Love poem
• 17855 Tweets
KEN MOONLIGHT PHOTO
• 15000 Tweets
投票率の低さ
• 14661 Tweets
ゼロ打ち
• 14641 Tweets
新婚旅行編
• 14487 Tweets
私のドリームユニット
• 14389 Tweets
解散総選挙
• 13263 Tweets
#TOTARS
• 11346 Tweets
#だれかtoなかい
• 11157 Tweets
#アンチヒーロー
• 10734 Tweets
Pinned Tweet
As
#oncologytrainees
prepare for their first
#patientencounter
, the
#SPIKES
protocol is often a good starting point. What advise do you have for
#trainees
when
#deliveringbadnews
?
@marklewismd
@NarjustDumaMD
@GlopesMd
@mtmdphd
@VPrasadMDMPH
@DevikaDasMD
@MayoHemeOnc
#HOFellowLife
32
55
192
As
@HemOncFellows
,
#bcsm
management has become increasingly complex! Below is a
#study
guide for
#MedOnc
#MedEd
fellows I have been working on :
What do you think? 🧐
@IlanaSchlam
@PTarantinoMD
@OncBrothers
@rleonferre
🛑
#WorkinProgress
#NotMedicalAdvice
🙏
#InputsWelcome
40
176
494
Excited for
@IASLC
#TTLC23
#TTLC2023
to hear the latest on 🫁
#LCSM
!
@HemOncFellows
, prepare for the meeting with
#studyguide
for
#NSCLC
treatment! ⬇️
#clinicaltrials
are imp to consider!
#NotMedicalAdvice
#InputsWelcome
🙏
@OncoAlert
@MayoHemeOnc
@MatthewHoMD
@OncMedEdCoP
10
117
353
Thrilled to announce my next adventure as a Thoracic/Phase 1 Medical Oncologist with
@ONealCancerUAB
!
Heartfelt gratitude for the support of my family, colleagues, and mentors. 🙏🏻🙏🏻
Y’all! Let’s connect at
@ASCO
#ASCO23
to discuss partnerships, collaborations and trials in…
70
9
293
🎄🎅 arrived early this year, thanks to
@MayoClinic
@MayoCancerCare
!
Honored and grateful to be conferred the rank of “Assistant Professor of
#Medicine
”
@MayoClinic
📜 ! Thank you to all who believed in me!
@MayoHemeOnc
🙏🏻🙏🏻
57
16
259
Are you looking forward to the exciting data being presented
@ASCO
#GU23
! 📈
Prepare yourself 📚 with this study guide on
#RCC
#renalcellcancer
#kidneycancer
before
#GU23
!
#InputsWelcome
#NotMedicalAdvice
@OncoAlert
@shilpaonc
@neerajaiims
@crisbergerot
@montypal
7
93
239
Step 1⃣, let's review what we know already!
👇
#algorithm
created with
@MatthewHoMD
giving 🔍into current Rx, credit
@NCCN
@JackWestMD
PDF: , blue text 👉 hyperlinks to the trials for 💊💉
Hoping this is📖🔖resource for
#patients
, and
#providers
@OncoAlert
27
100
236
#ASCO22
Small Cell Lung Cancer📰🧵
1⃣st review what we know already!
👇
#algorithm
created with
@MatthewHoMD
for
#SCLC
Rx, credit:
@NCCN
@JackWestMD
PDF: , blue text 👉 hyperlinks to trials for💊💉
Another🔖resource for
#patients
/
#providers
@OncoAlert
#ASCO22
Abstracts released today! Let's dig into some
#LCSM
studies of interest, trying to create 🧵here and 👀 for
#pre
-
@ASCO
discussion!
@OncBrothers
@OncoAlert
@StephenVLiu
@JackWestMD
@n8pennell
@FordePatrick
@AMansfieldMD
@LaurenByersMD
, hoping to meet
#LCSM
experts
#IRL
!
1
8
33
12
80
191
#ESMO22
@myESMO
is 🔜, so let’s review where we were
@ASCO
#ASCO22
in
#LCSM
to prepare ourselves! We (
@FawziAbuRous
@esinghimd
@msalmanfaisal
@drRTee
) review major “
#Lung
#Cancer
Treatment Advances ⏩ in 2022” in
#CancerInvestigation
@HemOncFellows
@OncoAlert
@LUNGevity
@IASLC
8
76
173
It’s official 🎉 My first
#grant
as faculty and PI few months into my first year on faculty! 🙏 Could not have asked for more!
@ONealCancerUAB
@lcrf_org
Thank you to all my mentors and colleagues who brought me here!
@HemOncFellows
@LungCancerRx
@MayoHemeOnc
@IMG_Oncologists
LCRF has announced 3 research grant awards funded by Daiichi Sankyo and AstraZeneca, focused on further developing the understanding of the proposed mechanism of action of antibody drug conjugates (ADCs).
#LungCancer
@ADesaiMD
@NSethakorn
Carl Gay, MD, PhD
1
6
22
35
6
166
"
#Antigen
#presentation
in
#cancer
: insights into tumour immunogenicity and immune evasion"
@NatureRevCancer
Jhunjhunwala et al. describe mechanisms of immune evasion by alteration of antigen repertoire presented on tumors
@OncoAlert
1
58
161
4
5
154
Out now! ⚡️
@NatRevClinOncol
"
#circulating
tumour DNA 🧬 — looking beyond the blood 🩸" discuss
ctDNA from non-blood sources, focusing on urine, cerebrospinal fluid, and pleural or peritoneal
fluid, and complementary role to blood ctDNA analysis
@Oncoalert
@isliquidbiopsy
3
63
151
⚡️Out now in
@JAMAOnc
#PatientPage
discussing the "Perioperative Therapy in Early-Stage Lung Cancer"
#LCSM
with
@AnaVManana
@JackWestMD
@Oncoalert
@HemOncFellows
Use this 📜 to discuss/navigate the expanding landscape of
#periop
#IO
with
#patients
👨⚕️👩⚕️
4
40
144
"3rd
#gen
#EGFR
and
#ALK
inhibitors: mechs. of resistance and management"
@NatRevClinOncol
👏 article by
@JessicaJLinMD
@LeciaSequist
discussing:
💊
#Osimertinib
,
#Lorlatinib
‼️ Resistance: On/Off 🎯
🔑 Rx
#pearls
@OncoAlert
@EGFRResisters
@ALKLungCancer
2
55
142
Excellent review of "Biliary tract cancer" in
@TheLancet
describes the presentation, evolution of Rx options,
#targeted
#therapy
and
#immunotherapy
. Exciting to see the progress made over the years!
@OncoAlert
@GICancer
@curecc
@CCA_Alliance
1
46
133
Really exciting year for
#KRASG12C
#LCSM
with 📊📈presented
@AACR
@ASCO
#ASCO22
and now
@IASLC
#WCLC22
!
Here is a
#Onc1Slider
on
#KRAS
#G12C
#LCSM
@HemOncFellows
everything you need to know 🎯!
@OncoAlert
@Oncbrothers
@KRASKickers
@Amgen
@Mirati
@MayoHemOnc
1
48
128
Excited to receive
@ConquerCancerFd
@ASCO
#Merit
🏆 🥈🙏🏻
@MayoHemeOnc
& 👏🏻 to friends
@JithmaA
@IrbazRiaz
@JPritchettMD
@MayoCancerCare
&
#Twitteratis
✨🌟
@TeresaSAmaral
@TimothyJBrownMD
@NazliDizman
@ArielleElkrief
@amarkelkar
@Chrislabaki1
@BiagioMd
&
@HemOncFellows
@OncoAlert
26
6
129
“Missing the target in cancer therapy”
@NatureCancer
discusses how for many lethal malignancies, the majority of clinical trials are conducted with patients who do not have biomarkers and hence they miss the target.
@OncoAlert
@jacobadashek
@Dr_R_Kurzrock
1
40
125
Humbled, Grateful 🙏 and honored to be the recipient of
@ASCO
Young Investigator Award (
#YIA
) in Mesothelioma
@ConquerCancerFd
and be among the "Brightest Minds in Cancer Research"! Privileged to work on
#ICI
in
#Mesothelioma
@MayoHemeOnc
@MayoCancerCare
@OncoAlert
@AMansfieldMD
32
11
125
Out now! The
#first
data from
#CCC19
in
@TheLancet
demonstrating why
#COVID19nCancer
is important since
#cancer
patients are uniquely vulnerable. Full paper at:
@OncoAlert
@COVID19nCCC
#Visualabstract
below:
4
56
110
2
33
108
Out now! ⚡️
@LungCaJournal
:
Antibody-Drug Conjugates: A Promising Novel Therapeutic Approach in
#LCSM
! 🙏🏻 to co-authors
@PamelaAbdayem
@DrAlexAdjei
@dplanchard
!
@MayoHemeOnc
@MayoCancerCare
@OncoAlert
🙏🏻 also to mentors:
@AMansfieldMD
@KLeventakos
6
47
105
Excellent review of "Modes of Regulated Cell Death in
#Cancer
"
@CD_AACR
@OncoAlert
describes key RCD modalities apoptosis, entosis, necroptosis, pyroptosis, and ferroptosis.
@OncoAlert
2
42
104
📢 Just in!
@NCCN
NSCLC v1.2024! 🚀 Updates and additions:
1️⃣ Osimertinib + pemetrexed + (cisplatin/carboplatin) 💊
2️⃣ Amivantamab-vmjw + carboplatin + pemetrexed 🌟
3️⃣ Repotrectinib🌐
📚
#LungCancer
#lcsm
@LungCancerRx
@OncoAlert
2
39
96
Thank you
@JAMAOnc
for ✍️ my thoughts on similarities between ♟and 🦀!
As an oncologist the mantras of chess have been unexpectedly relatable, but I am hoping to use my learnings against a more formidable opponent! 🦀
@MayoHemeOnc
@HemOncFellows
9
23
95
Excellent 🩸
#ctDNA
study from
@TataMemorial
Behel et al.
@VanitaNoronha
in
@ClinicalLung
showing ctDNA clearance from plasma post Rx initiation prolongs the PFS and OS and be used as a
#predictive
marker for outcome in patients with 🧬
#EGFR
-m
#NSCLC
@OncoAlert
@EGFRResisters
7
24
94
🔥 "Immunotherapy-based
#combos
in
#mNSCLC
#LCSM
" with
@peters_solange
in Cancer Treatment Reviews!
We explore the
#landscape
of
#NSCLC
#Immunotherapy
➕
➡️ CTLA4, LAG3, TIM3, and other ✔️🏁
➡️ 💊
#TKI
, PARPi, 💉
#Cytokines
@HemOncFellows
@OncBrothers
4
33
90
🔥 Off the press! "
#Drugging
#KRAS
: current perspectives and state-of-art review"
@BioMedCentral
➡️KRASG12C now druggable:
#Sotorasib
✔️
➡️Many 🎯drugs under investigation
Amazing
#LCSM
#DreamTeam
@kaushalpar
@gbanna74
@StephenVLiu
@DralexGva
@VivekSubbiah
@Alfdoc2
@Oncoalert
4
40
89
#ELCC22
🫁 has been amazing thus far! Great data, educational sessions and
#presentations
on
#LCSM
! Summary
#infographic
on some new data presented at this amazing
@ESMO
@IASLC
meeting! Cannot wait for
#AACR22
#ASCO22
for more progress against
#LCSM
!
@HemOncFellows
@OncoAlert
3
37
89
"Biased Evaluation in Cancer Drug Trials—How Use of
#PFS
as the Primary End Point Can Mislead"
@JAMAOnc
by
@ian_tannock
and Dr. Booth is a must read for
@HemOncFellows
! Excellent piece on how PFS benefits may be spurious with no OS benefit!
@OncoAlert
5
31
86
Updated
@NCCN
v5.2023
#lcsm
are out!
🗝️ Category 1️⃣ for Perioperative Pembrolizumab from KN 671!
🙏 Thrilled to join the esteemed guideline panel, a pivotal resource during my training and ongoing practice. Eager to contribute to this vital resource for many!
@OncoAlert
8
18
87
I'm thrilled and grateful to represent
@UABMedicine
@UABNews
and join amazing colleagues on the
#Communications
#Committee
of
@IASLC
(International Association for the Study of Lung Cancer) 🎉🙌
Proud to be part of this fantastic association committed to studying and eradicating…
11
2
86
"Unlocking the potential of
#ADCs
- antibody–drug conjugates for
#cancer
" state-of-the-art review by Drago et al. in
@NatRevClinOncol
describes
#design
,
#MoA
and clinical
#efficacy
of ADCs
@OncoAlert
1
35
85
Excited to moderate
@ASCO
podcast on "
#Oncology
Training-Past,Present and Future: Part 1" with
@DeepaRangachari
@BIDMC_HOFellows
@rosensteinl
@MadisonConces
@ClevelandClinic
#MedEd
#OncMedEd
#OncTwitter
#MedTwitter
@MayoHemOnc
@HemOncFellows
🎙️:
3
21
79
🎉Excited for my 1st oral presentation at
#WCLC21
discussing the trends in
#drug
#pricing
for
#NSCLC
! Kudos
@IASLC
for "Moving Beyond New Drugs: What Else Matters" and grateful also for the
#EarlyCareer
🏆 which will enable me to learn from the best 🫁
#oncologists
!
@MayoHemeOnc
14
7
80
Curious Question for
#lcsm
experts:
#Osimertinib
costs $914/month, taking it for 3 years will be 395,223$ for a single patient with Stage IB-IIIA EGFRm NSCLC after resection to provide them DFS 89 v 53%, benefit and with no current
#OS
data- will it be sustainable?
@VPrasadMDMPH
22
16
78
So I asked
#ChatGPT
to write a poem on the new
@FDAOncology
approval of
#pembrolizumab
for resectable
#LCSM
today!
And I have to say I am quite impressed…👏🏻
Quite the optimistic poetry of life, that
#oncology
teaches us well!
@HemOncFellows
@OpenAI
5
4
74
🎉Excited to be an
#ASCO23
Featured voice
@ASCO
with stellar colleagues, and friends!
I will be tweeting about
#LCSM
, phase 1 trials and interesting drugs in the horizon for all things
#solidoncology
!
👇🏼 List of
#LCSM
abstracts of interest!
Follow these 🌟🌟
#OncTwitter
…
3
23
75
🎉 Early 🎄🎁
@IASLC
! Delighted to share that I've been accepted into
@IASLC
Academy 2024! Eager to embark on this enriching journey, connect with peers, mentors, and friends. Grateful for the opportunity! 🙏
@LungCancerRx
with 💪🏼 representation there!
@esinghimd
@FawziAbuRous
10
4
76
Excellent review of
#SCLC
#LCSM
"Emerging Strategies for Small Cell Lung Cancer Treatment"
@LuisPaz_Ares
@JAMAOnc
@JAMANetwork
@OncoAlert
@HemOncFellows
0
23
74
#ASCO22
#Plenary
Dr. Yoshino presents "Panitumumab (PAN)+ mFOLFOX6 versus bevacizumab (BEV)+ mFOLFOX6 in 1st-line left-sided RASwt
#crcsm
: PARADIGM trial!
➡️mOS: 37.9 mos vs 34.3 for Left-sided
➡️mOS: 36.2 vs 31.3 for overall
RR/R0 resection rates 🔼
@OncoAlert
@HemOncFellows
2
30
73
"
#Liquid
biopsy enters the clinic — implementation issues and future challenges"- great review in key issues, gaps, and implementation of 🩸🧬
@NatRevClinOncol
@nature
by
@GeorgeSledge51
@MIgnatiadis
@OncoAlert
0
23
69
Excellent review on "ALK+
#LCSM
: a moving target"
@NatureCancer
by Jaime Schneider
@JessicaJLinMD
and Alice Shaw describing
➡️Current
#treatment
paradigm
➡️Resistance
#mechanisms
and
#ongoing
trials/future strategies!
@Oncoalert
@HemOncFellows
0
25
71
Do you agree?
Amivantamab + Chemo is new 1L SOC for EGFR ex20ins adv NSCLC
@nicogirardcurie
et al. at
#ESMO23
with PAPILLON study
Amivantamab + CT:
⬆️ PFS (HR, 0.40); ⬆️ all subgroups
⬆️ ORR (73 vs 47%)
⬆️ DOR (9.7 vs 4.4 mo)
#NSCLCBrief
@LealTiciana
9
28
72
Very excited to join discussion 🎙on “Educating the
#NextGen
#Onc
Leaders” 🧑🎓👨🎓as a panelist with
@FDAOncology
! Thank you 🙏🏻
@PazVellanki
@drjennifergao
@AACR
#AACR22
for the opportunity! Come join the discussion tomorrow 10.15 am CST!
#MedEd
@MayoHemeOnc
@HemOncFellows
@OncoAlert
6
11
72
If you missed
@TumorBoardTues
with
@CharuAggarwalMD
today, here is a
#Onc1Slider
for on
#EGFR
ex20,
@HemOncFellows
everything you need to know 🎯!
@OncoAlert
@Oncbrothers
📜 , , ,
@NCCN
2
27
70
Thank you 🙏
@IASLC
for the Education Award for
#TTLC22
! I will be presenting on
#Lurbinectedin
beyond second-line in
#SCLC
#LCSM
🫁 from
@MayoHemeOnc
@MayoCancerCare
#cohort
with mPFS: 3.8 mths! Thankful to mentors
@MayoClinic
@KLeventakos
@AMansfieldMD
@DrAlexAdjei
!
@OncoAlert
12
9
68
📖 our new article in
@CCR_AACR
on
��Direct to patient clinical trials: One small step or a giant leap 🏃♂️?”
🎯
#precisiononcology
barriers overcome by a direct-to-patient outreach program via
#SoMe
and offering 🧬
#testing
@VivekSubbiah
@OncoAlert
🔗:
5
25
69
"Priority
#COVID19Vaccination
for Patients with
#Cancer
while Vaccine Supply Is Limited"
@AACRPres
@jsoriamd
and co-authors discuss need for prioritization of this high-risk group
@CD_AACR
@OncoAlert
@FDAOncology
2
32
69
🚨Very excited to be able to present 3 abstracts
@myESMO
#ESMOTAT23
! 🗞️Honored to lead different teams for our research focused on
#drugdevelopment
,
#ADCs
#LCSM
and
#healthcare
#disparities
! Thankful to colleagues for support and encouragement of ideas 💡
🧵👇🏼
@HemOncFellows
4
9
67
Delighted to present our
@ConquerCancerFd
@ASCO
funded YIA at
@IASLC
#NACLC22
“Survival Associations of T cell clusters with
#immunotherapy
in
#mesothelioma
” Big thanks to mentors
@MayoCancerCare
@AMansfieldMD
🙏🏻! Come visit us at PPD04.01 5.30 pm today!
6
14
66
The
#vaccine
#race
is on! Which is great for
#medicine
and the world! Obviously the scientific community awaits the detailed results for analysis but this is good news- here’s an update from
@Brief_19
on how these 2 vaccines compare!
@OncoAlert
@COVID19nCCC
@reverendofdoubt
1
26
68
Analysis of
#ctDNA
before/after
#Rx
with curative intent of patients with early-stage
#NSCLC
> detection of ctDNA with personalized assays can inform patient prognosis and guide Rx
@Annals_Oncology
@OncoAlert
0
28
67
4
5
66
Packing carry 💼 for
#ASCO22
😁, what else do I need with me?
[ ] 📲and 🔌
[ ] 💻and 🔌
[ ] 📒✒️
[ ] 💧Bottle
[ ]
#proteinbars
[ ] Business Cards
Any others tips for
@HemOncFellows
and others attending 1️��st
@ASCO
#ASCO22
event?
@VivekSubbiah
@neerajaiims
@OncoAlert
@GlopesMd
11
8
66
So excited to see Dr. Karen Kelly
@IASLC
discuss the advances in
#LCSM
at the Early Career Workshop, and utilize this image that me and
@MatthewHoMD
created! Kudos to the progress we have made, and really humbled to see our work being used
@OncoAlert
#WCLC22
@JackWestMD
0
20
65
Very excited to be a part of
@OncoAlert
’s first
#fellow
initiative! Humbled to be a selected by
#omcology
’s leading
#socialmediavoice
! Thank you
@OncoAlert
🙏🏻 for this great opportunity!
@MayoHemeOnc
@MayoCancerCare
11
5
66
#ASCO23
Bound! ✈️
🔔 Must see sessions 6/2/23
➡️ EGFR mutant Clinical Science Symposia Dr. Janne
@JackieAredoMD
@MNagasaka
@BenjaminBesseMD
➡️ New 💉💊 in
#Oncology
!
@rachnatshroff
@VivekSubbiah
Dr. Fizazi
➡️ Patient journey in
#LCSM
🚗
@DeepaRangachari
@rodriguezabreu
…
0
17
64
⚡️
@JTOonline
“2021 global lung cancer therapy landscape” Deb et al.
@acmoorephd
describe:
➡️ 707 new 💉💊
#LCSM
➡️ Most in adv. stages of
#clinicaltrials
➡️ Targeted 🧬 Rx in the non-immuno-oncology
➡️
#Immunooncology
💉expanding beyond PD-L1 axis!
@OncoAlert
@HemOncFellows
1
20
65
🔔 Don't miss out!
Join me,
@AndreaAnampaG
@cissamathias
🙋♀️🙋♂️ at
#ASCO23
🏛️
➡️June 3 at 🕗 8 AM CST!
I'm truly honored 🎖️ to chair a session with these ✨ on
“How to navigate 🧭 the annual meeting 🗓️ effectively.” This is your golden chance 🌟 to maximize your
@ASCO
…
3
22
61
Immune-checkpoint inhibition
#ICI
for resectable non-small-cell lung cancer
#lcsm
by stellar team:
@g_mountzios
@JordiRemon
@HendriksLizza
@ChristianRolfo
@FordePatrick
@BenjaminBesseMD
@VivekSubbiah
@MartinReck2
@jsoriamd
@peters_solange
now out in
@NatRevClinOncol
@OncoAlert
…
1
23
63
🚨Out in
@JTOonline
our editorial “Toxicity From Sotorasib after ICI: A Note of Caution and Reflections of Future Advancements in the Field”
@uabmedicine
@MayoCancerCare
@OncoAlert
@LungCancerRx
➡️ Also checkout report by Chour et al.’s French exp. ⬇️
1
23
62
@HemOncFellows
#Testicular
#cancer
management
#study
guide ⬇️ for
#MedOnc
#MedEd
fellows:
Thoughts? 🧐
@YAUpenile_tesCa
@Oncoalert
@Uroweb
@ESRUrology
@OncBrothers
Hopefully good prep for
#GU2023
@ASCO
and
#ITE
!
🛑
#WorkinProgress
#NotMedicalAdvice
🙏
#InputsWelcome
3
20
61
Excellent review
@NatRevClinOncol
"Harnessing
#bigdata
to characterize
#IO
related adverse events
#irAEs
"
@OncoAlert
👉
#BigData
resources for
#irAE
study:
#clinical
,
#RWD
and
#omics
👉 Identify
#risks
:
#demographic
and
#omic
🧬
@HemOncFellows
1
19
61
⚡️Just in time for weekend & before
#ASCO22
,
#CancerInvestigation
we present review on updates in
#LCSM
from
@myESMO
@IASLC
#ELCC22
led by dynamic duo
@s_arora96
@palashasawa
with
#expert
guidance
@HendriksLizza
🙏🏻!
@OncoAlert
@HemOncFellows
@gary_lyman
@NicoleKuderer
@DrJNaidoo
4
23
60
“Strategies to overcome
#ALK
➖ resistance in
#LCSM
#NSCLC
” in TLCR! 🚨
@OncoAlert
💡Strategies for
#resistance
to/maximize
#ALKi
➡️ Ongoing Trials
@ALKpositiveINT
🙏🏻
@christine_lovly
for
#mentorship
and
@JustinGainor
@JessicaJLinMD
for
#SpecialIssue
3
26
60
Missed
#COVID19nCancer
plenary in
#AACR20
@AACR
?
Here’s a thread to catch up on all the fascinating global research presented by:
@AACR
@AACRPres
#AntoniRibas
#LiZhang
@marinagarassino
@barlesi
#CarlosGomez
#LouisVoigt
#HongbingCai
cc:
@OncoAlert
@COVID19nCCC
@ASCO
@ASH_hematology
2
34
60
🚨 In
@isliquidbiopsy
journal
"Putting comprehensive 🧬 profiling of ctDNA to work"
We explore ctDNA's utility across 4 categories:
1️⃣ Established 💊 selection
2️⃣ Emerging
3️⃣ Incidental discovery of secondary genomic findings
4️⃣ Quantification
1
28
60
November is
#LungCancerAwareness
🗓️
I will be posting 1
#LCSM
#tweet
/day to spread awareness on
#LCSM
diagnosis/management!
Follow 👇🧵
#LCSM
#LetsFightTogether
!
Note: Anyone with 🫁 can have
#LCSM
@LUNGevity
@lcrf_org
@lcfamerica
@EGFRResisters
@KRASKickers
@ALKLungCancer
1
17
60
Excellent review of
#MilestonesinCancer
by
@nature
describes the
#greatest
#strides
we have made in
#oncology
- but for the
#GenZ
taking care of
#cancer
patients we still have
#MilestogoBeforeWeSleep
!
@OncoAlert
@COVID19nCCC
0
23
58
"Transforming the landscape of early cancer detection using blood tests" excellent commentary by Dr. Liu
@MayoCancerCare
describing the tumour cell-free DNA (cfDNA), genomic technologies and machine learning in
#screening
!
@nature
@BrJCancer
@OncoAlert
0
25
59
Had a great time
@TargetedOnc
sharing my story of what led me to oncology, my experience
@MayoHemeOnc
, my advice for
@HemOncFellows
and my hopes and aspirations for the future of
#lcsm
, and
#oncology
@uabmedicine
@ONealCancerUAB
@ASCOTECAG
@ASCO
@IASLC
🎙️ Targeted Oncology is thrilled to announce the first episode of
#EmergingExperts
, a new podcast highlighting emerging talents in the oncology field, drops this Friday! In this episode,
@ADesaiMD
of
@ONealCancerUAB
shares his experiences and advice. Stay tuned!
0
1
12
2
10
59
Bittersweet memories
@MayoHemeOnc
on last clinic day! 🥲
So thankful and grateful to be part of this program and of the
#cancer
journey of my patients! 🙏🏻 Really blessed to be an oncologist.
@HemOncFellows
Among all accolades and academic achievements, these and many other…
0
3
58
Grateful to
@IASLC
for the education award 🏆 and accepting our abstract for
#TTLC23
! Thank you to friend and mentor
@KLeventakos
@MayoHemeOnc
and everyone else who supported this effort!
👀 fordward to meeting many 🫁
#oncologists
and a great week of learning!
@HemOncFellows
10
5
59
#ASCO22
🎥 starts today! Looking forward to a presentations in
#LCSM
📄📰 starting at 1 pm CST today!
Amazing line up
@erica_nakajima
@AlexSpiraMDPhD
@CharuAggarwalMD
@ReckampK
@EnriquetaFelip
@JoelNealMD
and others!!
Before we start 🎥 ⬇️ for an overview of
#LCSM
landscape!
2
16
56
“
#COVID19
vaccination: the VOICE for patients with
#cancer
”
@NatureMedicine
describes the VOICE study (‘vaccination against COVID in cancer’) study of patients with solid malignancies undergoing active anticancer treatment.
@COVID19nCCC
@OncoAlert
2
26
57
🚨Out in
@ClinicalLung
our 📄 on “RWD with Lurbinectedin in 2L and beyond for ES-SCLC”
#lcsm
➡️ Modest efficacy: mOS 5.1-5.6 months, mPFS 2.1-3.4 months.
➡️ neutropenia, anemia, fatigue, No severe toxicities 🚫
🙏 We need to do more for
#SCLC
@MayoHemeOnc
@uabmedicine
@OncoAlert
4
20
58
🚨Latest review in
@NatRevClinOncol
“
#Radiotheranostics
in
#oncology
: current challenges and emerging opportunities”
@LewisLabMSKCC
@lisabodei
@ProfKHerrmann
@OncoAlert
@HemOncFellows
0
16
57
@myESMO
#ESMOAsia22
#LCSM
studies of interest!
➡️ CheckMate 722: Nivo/Chemo = Chemo for
#EGFRm
post TKI
@LungCAN
➡️ LASER-301: Lazertinib > Gefitinib
#EGFRm
#NSCLC
@EGFRResisters
@EgfrUk
➡️ ALTA-3: Brigatinib = Alectinib post crizotinib
@ALKLungCancer
@OncoAlert
3
18
58
Learning from the best!
@marklewismd
@MayoHemeOnc
alumni’s best practices for poster presentation!!
@OncBrothers
@OncoAlert
@HemOncFellows
@LungCancerRx
@GlopesMd
@mtmdphd
Kool
#LCSM
kids presenting their Kool research at
#ASCO23
P.S.:
@ADesaiMD
’s pose is inspired by
@marklewismd
@LungCancerRx
@HemOncFellows
@IMG_Oncologists
@jennifermarksmd
5
5
38
2
13
57
Great experience and learning working on this
@NatRevClinOncol
with stellar team 🌟🌟
@maryam_lustberg
@NicoleKuderer
and
@gary_lyman
to discuss acute toxicities in patients with
#cancer
receiving chemotherapy!
@OncoAlert
@HemOncFellows
@MayoHemeOnc
@DianaNrco
Full link 👇🏼
In a Review now online,
@NicoleKuderer
,
@ADesaiMD
,
@maryam_lustberg
and
@gary_lyman
explain the most common acute toxicities in patients with cancer receiving chemotherapy and discuss management options:
19
293
631
2
15
56
“
#COVID19Vaccine
guidance for patients with
#cancer
participating in
#clinicaltrials
”
@NatRevClinOncol
we discuss recs for vaccine, prioritizing patient with
#cancer
and that vaccine should'nt affect
#trialeligibility
@OncoAlert
@MayoHemeOnc
@COVID19nCCC
1
23
56
"High
#TMB
in
#NSCLC
#LCSM
and ⬆️Immune Infiltration and Improved Outcomes of
#PDL1
Blockade"
@JAMAOnc
@JAMANetwork
@DFCI
@MSKCancerCenter
@OncoAlert
🧬TMB cut off 19m/Mb assoc. with improved ORR,PFS and OS in this retrospective cohort study!
3
18
56
Found this along with
#paperwork
🗞📑 in clinic! This is why we do what we do! And why we will keep doing it! 🙏🏻Grateful to be caring for patients with
#cancer
. I wish I could tell them how privileged I am to be involved in their journey!
#MedEd
#PatientComesFirst
@MayoCancerCare
2
7
55
Out now! ⚡️⚡️"
#COVID19nCancer
: Review of Registry Based Pandemic Response" - unprecedented collaborations and innovations within
#oncology
with registries with >28,500 pts
@JAMAOnc
@MayoHemeOnc
@MayoCancerCare
@VincentRK
3
18
56
Excited to present
#ASCOQLTY22
@ASCO
"Post-protocol Rx in 1L
#IO
trials in
#NSCLC
"
#LCSM
➡️Low rates of
#crossover
and post-protocol IO in 1L trials
➡️?due to limited 🌏 availability?
🔼need consistency in reporting
@OncoAlert
🙏
@MayoCancerCare
@AMansfieldMD
@JackWestMD
3
15
55
@myESMO
#ESMO21
#Twitter
has been crazy! So much exciting data and potentially practice changing! Trying to keep up only via
#medtwitter
, this is so far I’ve gotten… what did I miss? Practice changing studies only, ones you will discuss with patients next week!
@OncoAlert
2
25
56
⚡️
@FDAOncology
grants "regular" approval
#capmatinib
400 mg BID 💊for metastatic
#LCSM
with MET ex14 skipping!
⏮️Acc. approval:
#GEOMETRY
mono-1
Now, with +63 pts/22 mth followup
➡️ORR: 68%, (1L) 44%, (2L)
➡️ mDOR: 16.6 & 9.7 mos
🛑S/E: 🫧🤢😬
👇
#Onc1Slider
METex14
@OncoAlert
1
17
56
Take a bow! 🙌🙌
@marklewismd
's
#engaging
#inspiring
and
#touching
talk "Lost in the Woods? Seeking Novel Therapies from the Patient’s Perspective"! Dr.
@marklewismd
epitomizes what a
#physician
,
#researcher
and
#advocate
every
#oncologist
should strive to be!
#ASCO20
@OncoAlert
1
17
55
5
4
55
My mom advised
“Surround Yourself With Those Who
#Inspire
You The Most”
So I caught on to the
#chirptycircle
trend and checked mine out!
And I’m doing exactly that
#Mom
! ✅
3
5
53
“Envisioning the future of precision
#oncology
trials”
@NatureCancer
@subhamadhavan
et al. discuss opportunities to improve cohort selection and trial enrollment for the future of PO trials! Excellent review of the current and future landscape !
@OncoAlert
2
23
52